These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8141512)

  • 1. Interview with Joachim Robert Kalden. What is going to happen tomorrow as far as DNA and anti-DNA antibodies are concerned?. Interview by P. Youinou.
    Kalden JR
    Ann Med Interne (Paris); 1993; 144(7):463-4. PubMed ID: 8141512
    [No Abstract]   [Full Text] [Related]  

  • 2. Interview with Ivan M. Roitt. What is going to happen tomorrow as far as glycosylation of IgG is concerned?. Interview by P. Youinou.
    Roitt IM
    Ann Med Interne (Paris); 1993; 144(6):389-91. PubMed ID: 8122821
    [No Abstract]   [Full Text] [Related]  

  • 3. Interview with Joaquim Coll. What is going to happen tomorrow as far as secondary Sjögren's syndrome is concerned?. Interview by P. Youinou.
    Coll J
    Ann Med Interne (Paris); 1993; 144(4):257-9. PubMed ID: 8368718
    [No Abstract]   [Full Text] [Related]  

  • 4. Interview with Robert Schwartz. What is going to happen tomorrow in the field exploring the relationship between viruses and autoimmunity?. Interview by P. Youinou.
    Schwartz R
    Ann Med Interne (Paris); 1992; 143(6):419-20. PubMed ID: 1295397
    [No Abstract]   [Full Text] [Related]  

  • 5. [Interview with Moncef Zouali: What is going to happen tomorrow in the field of lupus anti-DNA antibodies?].
    Zouali M
    Ann Med Interne (Paris); 1995; 146(5):316-8. PubMed ID: 8526316
    [No Abstract]   [Full Text] [Related]  

  • 6. Interview with Graham Hughes. What is going to happen tomorrow in the field of anti-phospholipid antibodies?. Interview by P. Youinou.
    Hughes G
    Ann Med Interne (Paris); 1992; 143(6):417-8. PubMed ID: 1295396
    [No Abstract]   [Full Text] [Related]  

  • 7. [An interview with Jean-Michel Dayer: what is going to happen tomorrow in the field of cytokines?. Interview by P Youinou].
    Dayer JM
    Ann Med Interne (Paris); 1992; 143(7):445-7. PubMed ID: 1300865
    [No Abstract]   [Full Text] [Related]  

  • 8. [Interview with Dominique Charron. What is going to happen tomorrow in the understanding of the functioning of HLA molecules?. Interview by P. Youinou].
    Charron D
    Ann Med Interne (Paris); 1995; 146(1):25-8. PubMed ID: 7741390
    [No Abstract]   [Full Text] [Related]  

  • 9. [An interview with Sylviane Muller by P Youinou. What is going to happen tomorrow in the field of synthetic peptides of autoantigens?].
    Muller S
    Ann Med Interne (Paris); 1993; 144(5):319-22. PubMed ID: 8291840
    [No Abstract]   [Full Text] [Related]  

  • 10. [Interview with Pierre Godeau, President of the Société Nationale Française de Médecine Interne. What is going to happen tomorrow in internal medicine?. Interview by Pierre Youinou].
    Godeau P
    Ann Med Interne (Paris); 1994; 145(1):3-6. PubMed ID: 8192278
    [No Abstract]   [Full Text] [Related]  

  • 11. Interview with Jean-Pierre Revillard. What is going to happen tomorrow as far as treatment of autoimmune disorders is concerned?
    Revillard JP
    Ann Med Interne (Paris); 1997; 148(1):11-4. PubMed ID: 9137693
    [No Abstract]   [Full Text] [Related]  

  • 12. Interview with Frank Hay. What is going to happen tomorrow as far as rheumatoid factor is concerned?
    Hay F
    Ann Med Interne (Paris); 1995; 146(7):479-80. PubMed ID: 8787288
    [No Abstract]   [Full Text] [Related]  

  • 13. Interview with Norman Talal. What is going to happen tomorrow as far as Sjögren's syndrome is concerned?
    Talal N
    Ann Med Interne (Paris); 1993; 144(1):21-2. PubMed ID: 8503601
    [No Abstract]   [Full Text] [Related]  

  • 14. Interview with Peter Lydyard. What is going to happen tomorrow as far as heat-shock proteins are concerned?
    Lydyard P
    Ann Med Interne (Paris); 1993; 144(2):97-8. PubMed ID: 8333667
    [No Abstract]   [Full Text] [Related]  

  • 15. Association of circulating antibodies against double-stranded and single-stranded DNA with thyroid autoantibodies in Graves' disease and Hashimoto's thyroiditis patients.
    Pedro AB; Romaldini JH; Americo C; Takei K
    Exp Clin Endocrinol Diabetes; 2006 Jan; 114(1):35-8. PubMed ID: 16450315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis.
    Czaja AJ; Morshed SA; Parveen S; Nishioka M
    Hepatology; 1997 Sep; 26(3):567-72. PubMed ID: 9303484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Augmentation of DNA breaks by anti-dsDNA antibody].
    Kubota T; Watanabe N
    Nihon Rinsho Meneki Gakkai Kaishi; 1996 Dec; 19(6):605-8. PubMed ID: 9081726
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical significance of anti-DNA antibodies].
    Shoenfeld Y; Stollar BD; Schwartz RS
    Harefuah; 1983 Dec; 105(11):371-3. PubMed ID: 6368336
    [No Abstract]   [Full Text] [Related]  

  • 19. Induction of anti-DNA antibodies in preautoimmune NZBxNZW F1 mice by immunization with a DNA-DNase I complex.
    Chimenti D; Marchini B; Manzini S; Bombardieri S; Migliorini P
    J Autoimmun; 2000 Aug; 15(1):9-13. PubMed ID: 10936023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-DNA antibodies in systemic lupus erythematosus: a case of mistaken identity?
    Pisetsky DS
    J Rheumatol; 1998 Feb; 25(2):195-7. PubMed ID: 9489804
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.